NASDAQ:KRYSKrystal Biotech Stock Price, Forecast & News

$48.50

+0.45 (+0.94 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$48.01

Now: $48.50▼

$50.27

50-Day Range

$43.10

MA: $51.37▼

$60.00

52-Week Range

$22.02

Now: $48.50▼

$66.85

Volume167,155 shs

Average Volume176,103 shs

Market Capitalization$843.22 million

P/E RatioN/A

Dividend YieldN/A

Beta1.1

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Krystal Biotech has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $79.80, Krystal Biotech has a potential upside of 64.5% from its current price of $48.50.
Amount of Analyst Coverage
Krystal Biotech has only been the subject of 4 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Krystal Biotech has received 234 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Krystal Biotech has received 231 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Krystal Biotech has received 50.32% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote “Outperform” if you believe KRYS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Krystal Biotech does not currently pay a dividend.
Dividend Growth
Krystal Biotech does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $129,210.00 in company stock.
Percentage Held by Insiders
Only 27.40% of the stock of Krystal Biotech is held by insiders.
Percentage Held by Institutions
66.21% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Krystal Biotech are expected to decrease in the coming year, from ($2.19) to ($2.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Krystal Biotech is -39.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Krystal Biotech is -39.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Krystal Biotech has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.39 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KRYS

Previous Symbol

CUSIPN/A

CIK1711279

Webwww.krystalbio.com

Phone412-586-5830

Debt

Debt-to-Equity Ratio0.01

Current Ratio46.38

Quick Ratio46.38

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$11.72 per share

Price / Book4.14

Profitability

EPS (Most Recent Fiscal Year)($1.20)

Net Income$-19,090,000.00

Net MarginsN/A

Return on Equity-10.05%

Return on Assets-9.73%

Miscellaneous

Employees37

Outstanding Shares17,386,000

Market Cap$843.22 million

Next Earnings Date8/3/2020 (Estimated)

OptionableNot Optionable

Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

How has Krystal Biotech's stock been impacted by COVID-19 (Coronavirus)?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KRYS shares have decreased by 2.8% and is now trading at $48.50. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Krystal Biotech?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Krystal Biotech.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Krystal Biotech.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech Inc (NASDAQ:KRYS) posted its quarterly earnings data on Monday, May, 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.13. View Krystal Biotech's earnings history.

What price target have analysts set for KRYS?

7 analysts have issued 1-year target prices for Krystal Biotech's stock. Their forecasts range from $60.00 to $100.00. On average, they anticipate Krystal Biotech's share price to reach $79.80 in the next twelve months. This suggests a possible upside of 64.5% from the stock's current price. View analysts' price targets for Krystal Biotech.

What are Wall Street analysts saying about Krystal Biotech stock?

Here are some recent quotes from research analysts about Krystal Biotech stock:

1. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (5/8/2020)
2. Cowen Inc analysts commented, "On 8/9, Intec reported 2Q19 with a net loss of ($10M) and ended the period with $21.6M in cash on the balance sheet. Operating expenses are expected to be reduced with the P3 trial in Parkinson’s disease now over. The company is evaluating the data for AP-CD/LD to determine what the next steps may be. While the P3 trial outcome was a disappointment, it’s worth noting that the delivery technology that is the foundation of Intec as a company, did deliver the levodopa as it was supposed to. In addition, there are subgroup data that suggest trial design could be different and potentially have success, in our view. Nonetheless, it’s too early to tell and as we await more clarity, we remain Hold rated." (8/15/2019)
3. Chardan Capital analysts commented, "We view the receipt of the FDA Therapy (RMAT) designation as a significant positive for the timelines on KB103. This news follows KB103 receiving the EMA Priority Medicines (PRIME) designation on 29 March. As we have noted, Krystal’s market cap is modest relative to companies with PRIME and/or RMAT/BTD designations. We again reiterate: We would not be surprised if Krystal’s market cap crosses $1 billion by 2020E. On today’s news, we update our detailed model, moving the probability of KB103 launch from 55% to 67%, leading to an increase in our 2030E KB103 sales estimate from $492.1 mm to $596.5 mm. With a reduction in our WACC from 12.4% to 11.9%, these changes lead to a 30% KRYS PT target increase, from $57.50 to $75. has demonstrated impressive wound closure data (albeit in small numbers of patients) in the GEM-1 and GEM-2 studies." (6/24/2019)

Has Krystal Biotech been receiving favorable news coverage?

Press coverage about KRYS stock has trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Krystal Biotech earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutKrystal Biotech.

Are investors shorting Krystal Biotech?

Krystal Biotech saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,420,000 shares, a decrease of 6.0% from the April 30th total of 1,510,000 shares. Based on an average daily trading volume, of 156,600 shares, the days-to-cover ratio is presently 9.1 days. Approximately 13.0% of the company's shares are sold short. View Krystal Biotech's Current Options Chain.

Who are some of Krystal Biotech's key competitors?

Some companies that are related to Krystal Biotech include Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), Adaptimmune Therapeutics (ADAP), Editas Medicine (EDIT), Twist Bioscience (TWST), Mesoblast (MESO), I-Mab (BDTX) and Beam Therapeutics (BEAM). View all competitors.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Crispr Therapeutics (CRSP), ImmunoGen (IMGN), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Editas Medicine (EDIT), Iovance Biotherapeutics (IOVA), Kura Oncology (KURA) and Minerva Neurosciences (NERV).

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:

Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 54)
Ms. Suma M. Krishnan, Founder, COO & Director (Age 54)
Ms. Pooja Agarwal, VP of Product Devel. (Age 40)
Mr. Antony A. Riley, Chief Financial Officer (Age 51)
Ms. Gloria Lin, Accounting Mang.

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include Redmile Group LLC (6.05%), BlackRock Inc. (4.76%), State Street Corp (2.69%), Lord Abbett & CO. LLC (1.25%), Geode Capital Management LLC (0.96%) and Pictet Asset Management Ltd. (0.85%). Company insiders that own Krystal Biotech stock include Daniel Janney, Krish S Krishnan and Suma Krishnan. View institutional ownership trends for Krystal Biotech.

Which major investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Invesco Ltd., Redmile Group LLC, Morgan Stanley, Alps Advisors Inc., Blair William & Co. IL, Parametric Portfolio Associates LLC, and Bank of New York Mellon Corp. Company insiders that have sold Krystal Biotech company stock in the last year include Daniel Janney, Krish S Krishnan, and Suma Krishnan. View insider buying and selling activity for Krystal Biotech.

Which major investors are buying Krystal Biotech stock?

KRYS stock was bought by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Aviva PLC, Wells Fargo & Company MN, BlackRock Inc., Lord Abbett & CO. LLC, Atom Investors LP, JPMorgan Chase & Co., and Martingale Asset Management L P. Company insiders that have bought Krystal Biotech stock in the last two years include Krish S Krishnan, and Suma Krishnan. View insider buying and selling activity for Krystal Biotech.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $48.50.

How big of a company is Krystal Biotech?

Krystal Biotech has a market capitalization of $843.22 million. The company earns $-19,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Krystal Biotech employs 37 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff